These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 34976821)

  • 1.
    Havaei SM; Aucoin MG; Jahanian-Najafabadi A
    Front Oncol; 2021; 11():781800. PubMed ID: 34976821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Immunotoxins Containing
    Mazor R; Pastan I
    Front Immunol; 2020; 11():1261. PubMed ID: 32695104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Diphtheria Toxin-Based Therapy: A Review Article.
    Shafiee F; Aucoin MG; Jahanian-Najafabadi A
    Front Microbiol; 2019; 10():2340. PubMed ID: 31681205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights on
    Morgan RN; Saleh SE; Farrag HA; Aboshanab KM
    Ther Deliv; 2023 Jan; 14(1):31-60. PubMed ID: 36950853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical Issues in the Development of Immunotoxins for Anticancer Therapy.
    Kim JS; Jun SY; Kim YS
    J Pharm Sci; 2020 Jan; 109(1):104-115. PubMed ID: 31669121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxetumomab Pasudotox: First Global Approval.
    Dhillon S
    Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.
    Brinkmann U; Brinkmann E; Pastan I
    Mol Med; 1995 Jan; 1(2):206-16. PubMed ID: 8529099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted toxins in brain tumor therapy.
    Li YM; Hall WA
    Toxins (Basel); 2010 Nov; 2(11):2645-62. PubMed ID: 22069569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxins in the treatment of hematologic malignancies.
    Kreitman RJ; Pastan I
    Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
    Amoozadeh S; Hemmati M; Farajollahi MM; Akbari N; Tarighi P
    Cancer Invest; 2019; 37(10):546-557. PubMed ID: 31597492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteria-derived chimeric toxins as potential anticancer agents.
    Khoshnood S; Fathizadeh H; Neamati F; Negahdari B; Baindara P; Abdullah MA; Haddadi MH
    Front Oncol; 2022; 12():953678. PubMed ID: 36158673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Resistance to Immunotoxins Containing
    Dieffenbach M; Pastan I
    Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32630017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
    Choe M; Webber KO; Pastan I
    Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
    Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
    Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.